News | May 02, 2024
Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
2024 full-year revenue guidance raised by US$ 2 billion
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Sales reflect continued strong growth in oncology and vaccines
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Global Phase-3 study initiation expected in the second half of 2024
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Subscribe To Our Newsletter & Stay Updated
